TapewireFind a company

person · Reporting owner

Wilson Martin

Disclosed activity across 2 companies

Tapewire entity
21206
SEC CIK
0001704342

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627General CounselSeptember 11, 2026September 16, 2026
Teligent, Inc.TLGT · Entity 134764General CounselFebruary 19, 2019February 21, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ROCKET PHARMACEUTICALS, INC.

Report date September 11, 2026 · Filed September 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect598,489 Reported balance After 2026-09-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-11 · Sale · Disposed 75,364 · Balance 598,489

F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Teligent, Inc.

Report date February 19, 2019 · Filed February 21, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2029-02-19Direct193,712 Reported balance After 2019-02-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-02-19 · Grant · Acquired 193,712 · Balance 193,712

F1: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on February 19, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on February 19, 2020.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 11, 2026 Filed Sep 16, 2026 00:27 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 75,364 $3.40 $256,463.69
Disclosure

SEC source: 0001140361-26-036688 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 598,489

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
August 18, 2026 Filed Aug 20, 2026 21:30 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 631 $3.38 $2,133.41
Disclosure

SEC source: 0001140361-26-033915 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 673,853

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
August 13, 2026 Filed Aug 17, 2026 21:50 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 3,493 $3.38 $11,809.83
Disclosure

SEC source: 0001140361-26-033413 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 674,484

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
May 19, 2026 Filed May 21, 2026 20:06 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 662 $3.01 $1,995.27
Disclosure

SEC source: 0001140361-26-022446 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 677,977

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
May 13, 2026 Filed May 14, 2026 20:22 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 3,361 $3.61 $12,119.77
Disclosure

SEC source: 0001140361-26-021321 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 678,639

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
February 18, 2026 Filed Feb 20, 2026 21:09 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 1,376 $3.34 $4,593.09
Disclosure

SEC source: 0001140361-26-006317 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 682,000

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
February 13, 2026 Filed Feb 18, 2026 22:42 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 12,253 $3.31 $40,581.94
Disclosure

SEC source: 0001140361-26-006047 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 683,376

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantStock Option (Right to Buy) · Derivative 468,187 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001140361-26-005410 · form4.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 468,187

Underlying: Common Stock · 468,187 shares

Expires 2036-02-11

F3 · derivative.exercise_date: This option represents a right to purchase a total of 468,187 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantCommon Stock 311,813 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-005410 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 695,629

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · shares: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
November 18, 2025 Filed Nov 20, 2025 21:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 1,646 $2.98 $4,910.02
Disclosure

SEC source: 0001140361-25-042854 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 383,816

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Read SEC document
November 03, 2025 Filed Nov 10, 2025 21:25 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-041393 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 385,462

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: Represent RSUs that convert to common stock on a one-for-one basis. The RSUs will become fully vested on November 3, 2026.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 20:18 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantCommon Stock 150,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-034422 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 285,462

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on September 8, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
August 19, 2025 Filed Aug 20, 2025 21:00 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 588 $3.00 $1,761.65
Disclosure

SEC source: 0001140361-25-032090 · form4.xml · nonDerivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,462

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
August 18, 2025 Filed Aug 20, 2025 21:00 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 1,004 $3.07 $3,077.26
Disclosure

SEC source: 0001140361-25-032090 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,050

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
August 14, 2025 Filed Aug 18, 2025 20:35 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 12,109 $3.02 $36,557.07
Disclosure

SEC source: 0001140361-25-031760 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,054

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 587 $6.45 $3,783.80
Disclosure

SEC source: 0001140361-25-020159 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,163

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
May 16, 2025 Filed May 20, 2025 20:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 946 $6.53 $6,175.49
Disclosure

SEC source: 0001140361-25-019898 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,750

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 21:01 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 3,222 $10.58 $34,088.76
Disclosure

SEC source: 0001140361-25-005846 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,696

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 21:01 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantStock Option (Right to Buy) · Derivative 134,642 $0.00 Strike: $9.88 $0.00
Disclosure

SEC source: 0001140361-25-004297 · form4.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,642

Underlying: Common Stock · 134,642 shares

Expires 2035-02-11

F2 · derivative.exercise_date: This option represents a right to purchase a total of 134,642 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 21:01 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantCommon Stock 90,358 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-004297 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,918

F1 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 1,175 $13.05 $15,338.45
Disclosure

SEC source: 0001140361-24-047754 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,560

F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 20:26 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 1,027 $18.50 $19,003.61
Disclosure

SEC source: 0001140361-24-037931 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,735

F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
May 16, 2024 Filed May 20, 2024 20:29 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 1,048 $23.35 $24,470.80
Disclosure

SEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 4

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,762

F4 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Read SEC document
May 14, 2024 Filed May 20, 2024 20:29 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 Exercise / conversionRestricted Stock Units · Derivative 2,420 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-026873 · form4.xml · derivative · entry 5

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,947

Underlying: Common Stock · 2,420 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F1 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

F1 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
May 14, 2024 Filed May 20, 2024 20:29 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 Exercise / conversionCommon Stock 2,420 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
February 29, 2024 Filed Mar 4, 2024 23:48 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 4,100 $29.33 $120,257.10
Disclosure

SEC source: 0001140361-24-011168 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,680

F1 · price: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.37. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 16, 2024 Filed Feb 22, 2024 01:54 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantStock Option (Right to Buy) · Derivative 49,091 $0.00 Strike: $30.01 $0.00
Disclosure

SEC source: 0001140361-24-008890 · form4.xml · derivative · entry 3

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,091

Underlying: Common Stock · 49,091 shares

Expires 2034-02-16

F5 · derivative.exercise_date: This option represents a right to purchase a total of 49,091 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Read SEC document
February 16, 2024 Filed Feb 22, 2024 01:54 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantCommon Stock 16,644 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-008890 · form4.xml · nonDerivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,780

F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement").

F4 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
February 16, 2024 Filed Feb 22, 2024 01:54 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 SaleCommon Stock 3,576 $29.84 $106,700.69
Disclosure

SEC source: 0001140361-24-008890 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,136

F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement").

F2 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person.

F3 · shares: The shares of common stock were sold by the Reporting Person pursuant to an exemption to the Lock-Up Agreement in order to pay tax withholding obligations in connection with the vesting of RSUs. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 Exercise / conversionRestricted Stock Units · Derivative 9,712 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-008360 · form4.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,367

Underlying: Common Stock · 9,712 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.

F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:05 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 Exercise / conversionCommon Stock 9,712 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-008360 · form4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,712

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.

F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.

Read SEC document
February 14, 2023 Filed Feb 16, 2023 21:45 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantRestricted Stock Units · Derivative 29,079 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-007486 · form4.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,079

Underlying: Common Stock · 29,079 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.

F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
February 14, 2023 Filed Feb 16, 2023 21:45 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantStock Option (Right to Buy) · Derivative 87,147 $0.00 Strike: $20.04 $0.00
Disclosure

SEC source: 0001140361-23-007486 · form4.xml · derivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,147

Underlying: Common Stock · 87,147 shares

Expires 2033-02-13

F1 · derivative.exercise_date: This option represents a right to purchase a total of 87,147 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
February 14, 2023 Filed May 20, 2024 20:29 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 OtherRestricted Stock Units · Derivative 16,947 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-026873 · form4.xml · derivative · entry 7

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,947 shares

Expires not disclosed

F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

F1 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

F1 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

Read SEC document
February 14, 2023 Filed May 20, 2024 20:29 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 OtherCommon Stock 16,947 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 3

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,810

F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

Read SEC document
August 12, 2022 Filed Aug 16, 2022 21:24 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantRestricted Stock Units · Derivative 28,763 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-029888 · form4.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,763

Underlying: Common Stock · 28,763 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units will become fully vested on August 12, 2025.

F3 · derivative.expiration_date: The restricted stock units will become fully vested on August 12, 2025.

Read SEC document
August 12, 2022 Filed Aug 16, 2022 21:24 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantStock Option (Right to Buy) · Derivative 20,318 $0.00 Strike: $17.47 $0.00
Disclosure

SEC source: 0001140361-22-029888 · form4.xml · derivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,318

Underlying: Common Stock · 20,318 shares

Expires 2032-08-11

F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,318 shares of the Issuer's common stock, which will become fully vested and exercisable on August 12, 2025.

Read SEC document
August 12, 2022 Filed May 20, 2024 20:29 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 OtherRestricted Stock Units · Derivative 28,763 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-026873 · form4.xml · derivative · entry 6

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,763 shares

Expires not disclosed

F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

F3 · security: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

F3 · derivative.exercise_date: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025.

F3 · derivative.expiration_date: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025.

Read SEC document
August 12, 2022 Filed May 20, 2024 20:29 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 OtherCommon Stock 28,763 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,863

F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

F3 · security: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025.

F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

Read SEC document
December 06, 2021 Filed Dec 8, 2021 23:55 UTC ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $23.04 $0.00
Disclosure

SEC source: 0001140361-21-040891 · form4.xml · derivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-12-06

F1 · derivative.exercise_date: This option represents a right to purchase a total of 100,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on December 6, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:00 UTC Teligent, Inc. TLGT · Entity 134764 GrantStock Option · Derivative 193,712 $0.00 Strike: $1.62 $0.00
Disclosure

SEC source: 0001144204-19-009335 · tv514231_4.xml · derivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,712

Underlying: Common Stock · 193,712 shares

Expires 2029-02-19

F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on February 19, 2020.

Read SEC document
April 25, 2018 Filed Oct 22, 2018 21:45 UTC Teligent, Inc. TLGT · Entity 134764 Exercise / conversionRestricted Stock Units · Derivative 5,000 $0.00 $0.00
Disclosure

SEC source: 0001144204-18-054834 · tv505291_4.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents the right to receive one share of the Issuer's common stock.

F1 · kind: Vesting of restricted stock units ("RSUs") granted to the Reporting Person on April 25, 2017.

F3 · derivative.exercise_date: The RSUs vest ratably on an annual basis for three years beginning on April 25, 2018. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting.

F3 · derivative.expiration_date: The RSUs vest ratably on an annual basis for three years beginning on April 25, 2018. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting.

Read SEC document
April 25, 2018 Filed Oct 22, 2018 21:45 UTC Teligent, Inc. TLGT · Entity 134764 Exercise / conversionCommon Stock 5,000 $0.00 $0.00
Disclosure

SEC source: 0001144204-18-054834 · tv505291_4.xml · nonDerivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Vesting of restricted stock units ("RSUs") granted to the Reporting Person on April 25, 2017.

Read SEC document
March 22, 2018 Filed Apr 2, 2018 16:06 UTC Teligent, Inc. TLGT · Entity 134764 GrantRestricted Stock Unit · Derivative 11,052 $0.00 $0.00
Disclosure

SEC source: 0001144204-18-018612 · tv490094_form4.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,052

Underlying: Common Stock · 11,052 shares

Expires 2028-03-22

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on March 22, 2019.

Read SEC document
March 22, 2018 Filed Apr 2, 2018 16:06 UTC Teligent, Inc. TLGT · Entity 134764 GrantStock Option · Derivative 22,105 $0.00 Strike: $3.53 $0.00
Disclosure

SEC source: 0001144204-18-018612 · tv490094_form4.xml · derivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,105

Underlying: Common Stock · 22,105 shares

Expires 2028-03-22

F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on March 22, 2019.

Read SEC document
April 25, 2017 Filed Apr 26, 2017 16:45 UTC Teligent, Inc. TLGT · Entity 134764 GrantRestricted Stock Unit · Derivative 15,000 $0.00 $0.00
Disclosure

SEC source: 0001628280-17-004327 · wf-form4_149323953987247.xml · derivative · entry 2

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-04-25

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on April 25, 2018.

Read SEC document
April 25, 2017 Filed Apr 26, 2017 16:45 UTC Teligent, Inc. TLGT · Entity 134764 GrantStock Option · Derivative 40,000 $0.00 Strike: $8.15 $0.00
Disclosure

SEC source: 0001628280-17-004327 · wf-form4_149323953987247.xml · derivative · entry 1

Wilson Martin · CIK 0001704342 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2027-04-25

F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on April 25, 2018.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.